46% Best Overall Response Rate in the ITT Population 63% Best Overall Response Rate in the sAXL/GAS6 Biomarker High Population 6-month Progression-Free Survival Rate in the ITT Population of 79% 6-month Progression-Free Survival Rate of 91% in the 15 mg/kg Biomarker High Population 3-month Duration
HOUSTON, March 02, 2022 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, will present updated exposure-response analyses from the Phase 1b platinum-resistant ovarian cancer and Phase 1b clear cell
Preliminary top line data anticipated throughout 2022 HOUSTON, Jan. 31, 2022 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today announced that the Company has dosed the first patient in the
HOUSTON, Jan. 03, 2022 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease today announced that the company’s Chairman, Fred Eshelman, Pharm.D., through Eshelman Ventures, LLC, agreed to purchase a
HOUSTON, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing transformative, targeted therapeutics to treat life-threatening cancers, today announced that Gail McIntyre, Ph.D., DABT, Chief Executive Officer of Aravive, and Reshma Rangwala,
7 of 16 (44%) patients achieved best overall response of partial response Confirmed response in 5 of 7 (71%) patients who had at least 16 weeks of follow-up 14 of 16 (88%) patients demonstrated tumor decrease from baseline Batiraxcept has been well-tolerated with no dose-limiting toxicities
3 of 5 (60%) patients achieved a partial response All 5 patients treated demonstrated tumor decrease from baseline Batiraxcept has been generally well-tolerated with no dose-limiting toxicities Aravive to host conference call and webcast on November 12 at 8:30 a.m.
Dosed first patient in batiraxcept (formerly AVB-500) Phase 1b clinical trial in pancreatic adenocarcinoma Orphan drug designation granted by European Commission to batiraxcept in platinum resistant ovarian cancer New preliminary data from batiraxcept Phase 1b clinical trial in clear cell renal
HOUSTON, Oct. 01, 2021 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing innovative therapeutics to treat life-threatening diseases, today announced that new preliminary safety, pharmacokinetic, pharmacodynamic, and clinical activity data from the Phase
HOUSTON, Sept. 16, 2021 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing innovative therapeutics to treat life-threatening diseases, today announced that Gail McIntyre, Ph.D., DABT, Chief Executive Officer of Aravive, and Reshma Rangwala, M.D., Ph.D.,
